Abstract
The discovery of endothelin (ET) in 1988 has led to considerable effort to unravel its implication in health and disease and the mechanisms evoked by ET. ET-1 and related signaling aberrancies are believed to be implicated in the pathogenesis of diverse cardiovascular diseases, such as hypertension, atherosclerosis, hypertrophy and diabetes. The endothelin system consists of three potent vasoconstrictive isopeptides, ET-1, ET-2 and ET-3, signaling through two G protein coupled receptors, ETA and ETB, which are linked to multiple signaling pathways. Activated signaling transduction pathways include the modulation of the adenylyl cyclase/cAMP pathway through stimulatory (Gs) and inhibitory (Gi) G proteins, activation of the phosphoinositide pathway through the activation of proteins Gq/11, generation of oxidative stress, growth factor receptor-related mitogenic events, such as the activation of phosphatidylinositol-3 kinase pathway, phosphoinositide pathway and activation of the mitogen-activated protein (MAP) kinase cascade. The levels of ETA and ETB receptors as well as the signaling pathways activated by these receptors are altered in several cardiovascular diseases including hypertension, hypertrophy, atherosclerosis, diabetes, etc. In this review, we provide an overview of the signaling events modulated by ET-1 in vascular smooth muscle cells in both physiological and pathological conditions.
Keywords: atherosclerosis, diabetes, hypertension, ETA/B receptors, ET-1, ET-1 signaling, ET-1 synthesis.
Current Vascular Pharmacology
Title:Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Volume: 12 Issue: 2
Author(s): Yessica-Haydee Gomez Sandoval, Mohammed Emehdi Atef, Louis-Olivier Levesque, Yuan Li and Madhu B. Anand-Srivastava
Affiliation:
Keywords: atherosclerosis, diabetes, hypertension, ETA/B receptors, ET-1, ET-1 signaling, ET-1 synthesis.
Abstract: The discovery of endothelin (ET) in 1988 has led to considerable effort to unravel its implication in health and disease and the mechanisms evoked by ET. ET-1 and related signaling aberrancies are believed to be implicated in the pathogenesis of diverse cardiovascular diseases, such as hypertension, atherosclerosis, hypertrophy and diabetes. The endothelin system consists of three potent vasoconstrictive isopeptides, ET-1, ET-2 and ET-3, signaling through two G protein coupled receptors, ETA and ETB, which are linked to multiple signaling pathways. Activated signaling transduction pathways include the modulation of the adenylyl cyclase/cAMP pathway through stimulatory (Gs) and inhibitory (Gi) G proteins, activation of the phosphoinositide pathway through the activation of proteins Gq/11, generation of oxidative stress, growth factor receptor-related mitogenic events, such as the activation of phosphatidylinositol-3 kinase pathway, phosphoinositide pathway and activation of the mitogen-activated protein (MAP) kinase cascade. The levels of ETA and ETB receptors as well as the signaling pathways activated by these receptors are altered in several cardiovascular diseases including hypertension, hypertrophy, atherosclerosis, diabetes, etc. In this review, we provide an overview of the signaling events modulated by ET-1 in vascular smooth muscle cells in both physiological and pathological conditions.
Export Options
About this article
Cite this article as:
Sandoval Gomez Yessica-Haydee, Atef Emehdi Mohammed, Levesque Louis-Olivier, Li Yuan and Anand-Srivastava B. Madhu, Endothelin-1 Signaling in Vascular Physiology and Pathophysiology, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/1570161112666140226122054
DOI https://dx.doi.org/10.2174/1570161112666140226122054 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tertiary Hyperparathyroidism and Extra Skeletal Calcification in End Stage
Kidney Disease Patients: Case-series and Literature Review
New Emirates Medical Journal Antioxidative Actions of Statins: Potential Mechanisms for Antiathersclerotic Effects
Mini-Reviews in Medicinal Chemistry Candesartan Cilexetil Microemulsions for Transdermal Delivery: Formulation, in-vitro Skin Permeation and Stability Assessment
Current Drug Delivery Hub Genes and Immune Cell Infiltration in Hypoxia-Induced Pulmonary Hypertension: Bioinformatics Analysis and <i>In Vivo</i> Validation
Combinatorial Chemistry & High Throughput Screening Genetics in Diabetic Retinopathy: Current Concepts and New Insights
Current Genomics The Pragmatism of Polyphenols and Flavonoids Application as Drugs, from an Academic Lab to a Pharmacy Shelf
Current Pharmaceutical Design Renovascular Hypertension: Novel Insights
Current Hypertension Reviews Adenosine Myocardial Perfusion Imaging
Current Medical Imaging Meet our Editorial Board Member
Cardiovascular & Hematological Agents in Medicinal Chemistry Surfactant Replacement Therapy in Pediatric Acute Lung Injury/Acute Respiratory Distress Syndrome
Current Respiratory Medicine Reviews Role of PI3K/AKT, cPLA2 and ERK1/2 Signaling Pathways in Insulin Regulation of Vascular Smooth Muscle Cells Proliferation
Cardiovascular & Hematological Disorders-Drug Targets Targeting Angiogenesis in Rheumatoid Arthritis
Current Rheumatology Reviews The Role of 5-AMP-Activated Protein Kinase (AMPK) in Diabetic Nephropathy: A New Direction?
Current Enzyme Inhibition Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety How Drugs Influencing Central Blood Pressure Prevent Atherosclerosis Complications?
Current Pharmaceutical Biotechnology 1+1 > 2: Integration of the Host-directed Traditional Chinese Medicine and the Virus-targeted Modern Medicine in Control of COVID-19
Clinical Cancer Drugs Effects of Sacubitril/Valsartan <i>Versus</i> Telmisartan in Type 2 Diabetic or Pre-Diabetic Patients with Hypertension and Without Heart Failure: The Rationale and Design of A Randomized Clinical Trial
Cardiovascular & Hematological Disorders-Drug Targets Combinational Approaches Targeting Neurodegeneration, Oxidative Stress, and Inflammation in the Treatment of Diabetic Retinopathy
Current Drug Targets